Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.48 |
| ▸ | DGAT1 | O75907 | 4/20 | 0.44 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.38 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.38 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14729111 | 0.94 | GPR119 (0.55) | GPR119DGAT1KCNH2SLC6A9SLC6A5 | |
| SCHEMBL14729200 | 0.87 | GPR119 (0.52) | GPR119DGAT1HRH3 | |
| SCHEMBL14729105 | 0.86 | GPR119 (0.53) | GPR119DGAT1KCNH2ADORA2A | |
| SCHEMBL14729106 | 0.80 | GPR119 (0.51) | GPR119 | |
| SCHEMBL14729110 | 0.80 | GPR119 (0.49) | GPR119 | |
| SCHEMBL14729139 | 0.79 | GPR119 (0.56) | GPR119DGAT1 | |
| SCHEMBL14729188 | 0.79 | GPR119 (0.47) | GPR119DGAT1KCNH2ADORA2AHRH3 | |
| SCHEMBL14729112 | 0.79 | GPR119 (0.56) | GPR119 | |
| SCHEMBL2591328 | 0.79 | GPR119 (0.58) | GPR119 | |
| SCHEMBL14729103 | 0.78 | PIK3CD (0.41) | GPR119HRH3PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8940716-B2 | Bicyclic heteroaryl compounds as GPR119 modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-01-27 | — | — | US | disclosed |
| US-20130053345-A1 | BICYCLIC HETEROARLY ANALOGUES AS GPR119 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2013-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053345-A1 | BICYCLIC HETEROARLY ANALOGUES AS GPR119 MODULATORS | GPR119, GPR139, GPR4 | GPR119 1/4885DGAT1 707/4885NR1H2 227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.